Vasomune Therapeutics, Inc.
Vasomune Therapeutics is a private clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases associated with vascular dysfunction. Their lead drug candidate, Pegevongitide (AV-001), enhances the body's ability to reverse vascular endothelial instability and vascular leak, particularly in conditions such as Acute Respiratory Distress Syndrome (ARDS), hemorrhage, and following toxin exposure.
Industries
Nr. of Employees
small (1-50)
Vasomune Therapeutics, Inc.
180 John Street, Suite 305, Toronto, ON M5T 1X5
Patents
Agent for promoting angiogenesis and methods and uses thereof
2022-07-12 • US-11384130-B2
View Details
Agent for promoting angiogenesis and methods and uses thereof
2022-07-12 • US-11384130-B2
View DetailsProducts
AV-001 (PEGylated angiopoietin-1 mimetic peptide)
Investigational, fully synthetic PEGylated peptide therapeutic designed to activate the Tie2 receptor on endothelial cells to enhance vascular barrier integrity, reduce vascular leak and counteract vascular inflammation for indications driven by endothelial dysfunction.
AV-001 (PEGylated angiopoietin-1 mimetic peptide)
Investigational, fully synthetic PEGylated peptide therapeutic designed to activate the Tie2 receptor on endothelial cells to enhance vascular barrier integrity, reduce vascular leak and counteract vascular inflammation for indications driven by endothelial dysfunction.
Expertise Areas
- Vascular-targeted therapeutics
- Peptide drug design and PEGylation
- Preclinical in vivo disease models (ARDS, pneumonia, sepsis, AKI, hemorrhagic shock)
- Clinical trial management (Phase 1–2a)
Key Technologies
- PEGylated peptide therapeutics
- Receptor agonist biologics (Tie2 pathway activation)
- In vivo animal models of respiratory infection and sepsis
- Pharmacokinetic (PK) analysis
Key People
President & COO
Vice-President, Research & Scientific Affairs
Vice-President, Finance
Vice-President, Operations & Planning
President & COO
Vice-President, Research & Scientific Affairs
Vice-President, Finance
Vice-President, Operations & Planning
News & Updates
Vasomune Therapeutics has received Fast Track Designation from the US FDA for AV-001, a novel investigational medicine.
Vasomune Therapeutics has been selected to present its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit.
Vasomune and AnGes announced that AV-001 received a positive recommendation from the IDSMB for the Phase 2a study.
Vasomune Therapeutics has received Fast Track Designation from the US FDA for AV-001, a novel investigational medicine.
Vasomune Therapeutics has been selected to present its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit.
Vasomune and AnGes announced that AV-001 received a positive recommendation from the IDSMB for the Phase 2a study.